EQRx Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $2.25
- Today's High:
- $2.305
- Open Price:
- $2.29
- 52W Low:
- $1.58
- 52W High:
- $6.05
- Prev. Close:
- $2.28
- Volume:
- 1970283
Company Statistics
- Market Cap.:
- $891.87 million
- Book Value:
- 2.733
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -15.06%
- Return on Equity TTM:
- -19.03%
Company Profile
EQRx Inc had its IPO on 2021-12-20 under the ticker symbol EQRX.
The company operates in the Healthcare sector and Biotechnology industry. EQRx Inc has a staff strength of 362 employees.
Stock update
Shares of EQRx Inc opened at $2.29 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $2.25 - $2.31, and closed at $2.29.
This is a +0.44% increase from the previous day's closing price.
A total volume of 1,970,283 shares were traded at the close of the day’s session.
In the last one week, shares of EQRx Inc have slipped by -0.87%.
EQRx Inc's Key Ratios
EQRx Inc has a market cap of $891.87 million, indicating a price to book ratio of 0.9978 and a price to sales ratio of 0.
In the last 12-months EQRx Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-367683008. The EBITDA ratio measures EQRx Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, EQRx Inc’s operating margin was 0% while its return on assets stood at -15.06% with a return of equity of -19.03%.
In Q1, EQRx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
EQRx Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.62 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into EQRx Inc’s profitability.
EQRx Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.2806. Its price to sales ratio in the trailing 12-months stood at 0.
EQRx Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.38 billion
- Total Liabilities
- $59.88 million
- Operating Cash Flow
- $-40359000.00
- Capital Expenditure
- $444000
- Dividend Payout Ratio
- 0%
EQRx Inc ended 2024 with $1.38 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.38 billion while shareholder equity stood at $1.31 billion.
EQRx Inc ended 2024 with $0 in deferred long-term liabilities, $59.88 million in other current liabilities, 49000.00 in common stock, $-610140000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $368.36 million and cash and short-term investments were $1.33 billion. The company’s total short-term debt was $2,368,000 while long-term debt stood at $0.
EQRx Inc’s total current assets stands at $1.35 billion while long-term investments were $4.00 million and short-term investments were $957.58 million. Its net receivables were $0 compared to accounts payable of $20.73 million and inventory worth $0.
In 2024, EQRx Inc's operating cash flow was $-40359000.00 while its capital expenditure stood at $444000.
Comparatively, EQRx Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $2.29
- 52-Week High
- $6.05
- 52-Week Low
- $1.58
- Analyst Target Price
- $2.55
EQRx Inc stock is currently trading at $2.29 per share. It touched a 52-week high of $6.05 and a 52-week low of $6.05. Analysts tracking the stock have a 12-month average target price of $2.55.
Its 50-day moving average was $2.11 and 200-day moving average was $2.16 The short ratio stood at 11.33 indicating a short percent outstanding of 0%.
Around 1084.5% of the company’s stock are held by insiders while 7292.8% are held by institutions.
Frequently Asked Questions About EQRx Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company’s clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.